-
Pipeline
2024.02.29
S-483, a Pre-clinical Program for 21-Hydroxylase Deficiency, Was Selected as a Support Program of AMED
-
Pipeline
2024.02.29
SCO-240, a Clinical Program for Pediatric Growth Hormone Deficiency, Was Selected as a Support Program of AMED
-
Publication
2023.06.12
Presentation of clinical data of SCO-240 at the 96th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders
Page Top